

Proposals requesting access to ALTTO Data

Lapatinib-related rash and its impact on disease free survival following in the ALTTO Trial

The role of regional nodal irradiation in node-positive HER2-positive breast cancer patients treated with breast conserving surgery and axillary lymph-node dissection.

The effect of obesity, diabetes and anti-hyperglycemic drugs on disease-free and overall survival in patients enrolled in the ALTTO trial

Anatomy of ALTTO : Dissecting interim and final databases to understand the observed primary analysis results of dual HER2 inhibition

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance

Treatment-induced amenorrhea following adjuvant trastuzumab and/or lapatinib in premenopausal women with HER2-positive operable breast cancer enrolled in the ALTTO trial

Evaluation of disease-free survival and other time-to-event endpoints as surrogates for overall survival in the systemic therapy of HER-2-positive early breast cancer

Impact of body mass index (BMI) and weight change after breast cancer diagnosis and treatment in patients with early-stage HER2-positive breast cancer (ALTTO BIG 2-06).

Dissecting the effect of hormone receptor status expression in women with HER2-positive operable breast cancer treated with anti-HER2 agents in the ALTTO trial

To determine the impact of kinase vs helical domain PIK3CA mutations on both relapse free and overall survival in the adjuvant treatment of women with HER2-positive breast cancer.

Subpopulation Treatment Effect Pattern Plot (STEPP) Analysis of the Trastuzumab Control Arm in ALTTO

Tolerability of Adjuvant Trastuzumab or Trastuzumab and Lapatinib in Older Patients - a Sub-analysis of the ALTTO Trial

Impact of cardiac medication use on clinical outcomes of patients with early-stage HER2-positive breast cancer

Serious Adverse Events During Study Treatment in Older Patients– A Sub-analysis of the ALTTO Trial.

The prognostic performance of PREDICT+ in breast cancer patients with early-stage HER2-positive disease
The prognostic and predictive value of disease-free interval from trastuzumab completion in women with HER2-positive operable breast cancer with distant relapses after adjuvant anti-HER2 treatment
Cardiotoxicity Related to Systemic Adjuvant Anti-HER2 Therapies in the ALTO Trial (BIG 2-06/N063D)
Non-cancer Related Death in Older Patients with Breast Cancer - A Sub-analysis of the ALTO Trial.
POST-MASTECTOMY AND POST-NEOADJUVANT RADIOTHERAPY IN EARLY BREAST CANCER PATIENTS TREATED WITH ADJUVANT HER2-TARGETED THERAPY: AN ANALYSIS FROM ALTO
Do Clinical Outcomes Among Older Cancer Patients Differ Based on Continent? A Secondary Analysis of the ALTO Trial

Proposals requesting access to NeoALTO Data
Body mass index and response to neoadjuvant anti-HER2 therapies in early breast cancer patients: Analysis from NeoALTO Trial
Genetic predictors of lapatinib-related or lapatinib-exacerbated diarrhea, fatigue, cardiotoxicity, and neuropathy on neoALTO
PIK3CA mutations as predictor for response/resistance in HER2+ breast cancer with a special attention to subgroups and long-term outcome
Building genomic models that define associations between immune function genes and outcome following neoadjuvant trastuzumab or lapatinib alone or in combination.
Amplification of FGFR signaling and resistance to dual HER2 blockade.
RB-1 loss of function gene-signature (RBsig) as a tool to dissect the heterogeneity of HER2+/ER+ disease and as a marker of responsiveness to neoadjuvant chemotherapy plus anti-HER2 agents in breast cancer patients.
Combined clinical and marker analysis of EFS in NeoALLTO

Studying the impact of BMI on rates of pCR in patients treated with neoadjuvant trastuzumab +/- lapatinib in HER2-positive breast cancer
Integration of cell lines and patient tumors data for predicting drug response in cancer patients
Optimizing HER2-targeting using RNA and DNA based predictive algorithms
Markers of T cell dysfunction and benefit from HER2 blockade
Pathological complete response and long-term clinical benefit in HER2-positive breast cancer: the HER2-CTNeoBC pooled analysis
18F-FDG PET/CT and its association with survival outcomes and host/tumor features in NeoALTTO trial

Proposals requesting access to ALTTO & NeoALTTO Data
Pregnancies during and following adjuvant anti-HER2 targeted treatment with trastuzumab and/or lapatinib in patients with HER2-positive early-stage breast cancer enrolled in the NeoALTTO and ALTTO trials
Network approaches to predict drug response to anti-HER2 drugs in breast cancer patients
IMPACT OF ANTIBIOTICS IN EARLY BREAST CANCER PATIENTS TREATED WITH HER2-TARGETED THERAPY
Mechanistic contribution and prognostic relevance of immune-mediated cytotoxicity during neoadjuvant treatment with trastuzumab
Prognostic and Predictive Role of the Intratumoral HER2/CEP17 Ratio in Women treated with Trastuzumab, Lapatinib, or Trastuzumab plus Lapatinib, in the ALTTO and Neo-ALTTO Trials: A Biomarker Analysis